A recent article in the Telegram discussed translation medicine, a discipline that tries to reduce the gaps between discoveries made in the research laboratory and their application in clinical practice.
In a blog a couple of weeks ago, I summarized the many anti-chronic disease efforts PhRMA supports and explained why we’ve made those commitments. High on the list of programs we back is the Partnership to Fight Chronic Disease (PFCD) and a recent statement by the Centers for Disease Control and Prevention explains why:
Last week the CMS Office of the Actuary, following legislatively proscribed duties, stated that actual and projected Medicare expenditures for 2011 through 2015 are low enough that they will not trigger the Independent Payment Advisory Board (IPAB) to recommend binding cuts to the Medicare program.
PhRMA would like to congratulate Michael Froman, who today was nominated by President Obama to be the new United States Trade Representative. This position is critically-important as our nation strives to improve its standing in the global marketplace and create new, high-paying jobs that will propel our economy in the 21st Century. His extensive experience working on important economic issues will certainly benefit our nation as we look toward a trade policy that will build a foundation for future prosperity.
Not taking our medicines as prescribed is a serious problem and finding remedies to help patients stick with their treatments as directed would go a long way to better health, not to mention helping control healthcare costs.
It was suggested yesterday that drug companies aren’t putting enough resources into developing medicines for mental illness. This couldn’t be further from the truth. The reality is that as an industry, we are deeply vested in finding new treatments for patients suffering from debilitating neurological and mental health illnesses.
The question of the day is: what can we do to meet the enormous healthcare challenges ahead? Truly, it’s the question of the decade. The challenges are real. The clock is ticking. What we do today, tomorrow, next year and beyond to set sound policies in Washington, state capitals and around the world will mean the difference between solving problems and simply coping with the onslaught of disease.
“A strong intellectual property rights system encourages investment by millions of people in the United States and abroad to engage in ongoing innovation. This is critical for future economic growth in the United States and elsewhere. America’s founding fathers considered this to be so important that they included the legal basis for our national patent and copyright system in the U.S.
Innovators are progressing, and as a result, so is our understanding of the work they are doing.
Cutting edge cancer treatments offer patients hope in their battle against devastating diseases. They typically treat some of the most severe or rare diseases, where previously there were inadequate options. Since 1980, life expectancy for cancer patients has increased by about three years and over 80 percent of those gains are attributable to new treatments, including medicines.
Today is the World Intellectual Property Organization’s World Intellectual Property Day, and it couldn’t be more relevant.
As I mentioned in a post earlier this week, the human toll of blood cancers is a very personal issue for me. I have witnessed first-hand the valiant struggle that patients endure, and the sad reality that despite tremendous progress to date, we cannot always stop disease progression. This is why – above all else – I am excited by the promising, innovative research reflected in a reported released today by PhRMA.
The Hill’s Congress Blog featured a blog post today from John J. Castellani, president and CEO, PhRMA, about the Senate Aging Committee hearing on the National Alzheimer's Plan.
Check your calendar and hop online; chances are, you’re probably near one of the DEA’s National Take Back Day’s nearly 5,500 disposal sites where local law enforcement will supervise a free, anonymous take back program between 10:00 a.m. – 2:00 p.m. this Saturday, April 27.
The Trans-Pacific Partnership (TPP) agreement has the potential to be an economic game-changer for the United States. Opening the growing markets of the Asia Pacific region would increase trade and exports, help continue our economic recovery and create new, high-paying jobs for American workers.
PhRMA explores the potential medicines in the biopharmaceutical pipeline on a regular basis through our Medicines in Development reports and other related efforts. Simply put, the pipeline is the foundation of PhRMA member companies.
A new report on the antibiotic pipeline is causing renewed concern given the emergence of antibiotic-resistant “superbugs” with high mortality rates.
Antibiotic-Resistance Poses Grave Danger